Abstract:Schistosoma mansoni infection leads to chronic schistosomiasis and severe hepatic fibrosis. We designed a liver-targeted lipid nanoparticle (LNP) carrying siRNA against type I TGF-β receptor (TGFβRI) mRNA to treat schistosomiasis-induced liver fibrosis in BALB/c mice. Knockdown of TGFβRI by LNP-siTGFβRI reduced LX-2 cell activation in vitro and alleviated liver fibrosis in S . mansoni -infected mice. αSMA and Col1a1 fibrotic markers in the liver tissues of infected mice were significantly suppressed in the treatment groups. In the serum of the LNP-siTGFβRI-treated groups, cytokines IFNγ, IL-1α, IL-6, IL-12, RANTES (CCL5), and TNFα increased, while GM-CSF, IL-2, IL-4, IL-10, IL-13, and KC (CXCL1) decreased compared to the control. Cell proportions were significantly altered in S . mansoni -infected mice, with increased CD56d NK cells and decreased CD19 + B cells and CD4 + T cells compared to naïve mice. Following LNP-siTGFβRI treatment, CD56d NK cells were downregulated, while B and memory Th cell populations were upregulated. The density of fibrotic regions significantly decreased with LNP-siTGFβRI treatment in a dose-dependent manner, and no systemic toxicity was observed in the major organs. This targeted siRNA delivery strategy effectively reduced granulomatous lesions in schistosomiasis-induced liver fibrosis without detectable side effects. This present study indicates that a liver-targeted lipid nanoparticles (LNPs) carrying siRNA against type I TGF-β receptor (TGFβRI) mRNA that we designed could be used to treat schistosomiasis-induced liver fibrosis. We demonstrated a liver-specific accumulation of LNPs upon intravenous injection in BALB/c mice at drug dose of 0.1 or 1 mg/kg twice a week for 4 weeks. In vitro and in vivo experiments both revealed reduced activation of HSC and alleviated liver fibrosis in S. mansoni-infected mice. The fibrotic markers αSMA and Col1a1 and serum cytokines including GM-CSF, IL-2, IL-4, IL-10, IL-13 and KC (CXCL1) from liver tissues were significantly suppressed in LNP-siTGFβRI treatment groups. FACS results indicated that following LNP-siTGFβRI treatment, CD56d NK cells showed downregulation, while B cell and memory Th cell populations were upregulated. Histological analysis showed the density of fibrotic regions were significantly decreased with LNP-siTGFβRI treatment in a dose-dependent manner and no systemic toxicity was observed in major organs. In this study, we provide a potentially targeted siRNA delivery strategy reducing granulomatous lesions for schistosomiasis-induced liver fibrosis treatment without detectable side effects. It is hoped that this study will provide effective new treatments for liver fibrosis caused by schistosomiasis in the future.

Intrasplenic Transplantation of IL-18 Gene-Modified Hepatocytes: an Effective Approach to Reverse Hepatic Fibrosis in Schistosomiasis Through Induction of Dominant Th1 Response

IFN‐γ Gene Therapy by Intrasplenic Hepatocyte Transplantation: a Novel Strategy for Reversing Hepatic Fibrosis in Schistosoma Japonicum‐infected Mice

Study on the efficacy of IFN-γ gene-modified murine hepatocytes against hepatic fibrosis in Schistosomiasis japonica

Effects of IL-18 on immunoregulation in mice infected with Schistosoma japonica following praziquantel treatment

[Effects of Intrasplenic Transplantation of IL-18 Gene-Modified Fetal Hepatocytes on Mouse Immune Function]

Antitumor Effects Of Interleukin-18 Gene-Modified Hepatocyte Cell Line On Implanted Liver Carcinoma

The Protective Effect of Intrasplenic Transplantation of Ad-IL-18BP/IL-4 Gene-Modified Fetal Hepatocytes on ConA-induced Hepatitis in Mice.

Intrasplenic Transplantation of Syngenic Hepatocytes Modified by IFN-γ Gene Ameliorates Hepatic Fibrosis in Rats

Activation of Primary Hepatic Stellate Cells and Liver Fibrosis Induced by Targeting TGF-β1/Smad Signaling in Schistosomiasis in Mice

Single-cell RNA sequencing to dissect the immunological network of liver fibrosis in Schistosoma japonicum-infected mice

In Vivo Distribution and Gene Expression of Genetically Modified Hepatocytes after Intrasplenic Transplantation

The Efficacy of NP11-4-derived Immunotoxin Scfv-Artesunate in Reducing Hepatic Fibrosis Induced by Schistosoma Japonicum in Mice.

In vivo Therapeutic Effects and Mechanisms of Hydroxyasiaticoside Combined With Praziquantel in the Treatment of Schistosomiasis Induced Hepatic Fibrosis

Recombinant Sj16 Protein with Novel Activity Alleviates Hepatic Granulomatous Inflammation and Fibrosis Induced by Schistosoma Japonicum Associated with M2 Macrophages in a Mouse Model

Autophagy in hepatic progenitor cells modulates exosomal miRNAs to inhibit liver fibrosis in schistosomiasis

Effect of Recombinant Interferon-γ Combined with Anluohuaxianwan on Expression of TIMP-1 and TGF-β1,mRNA in Hepatic Fibrosis of Mice Infected with Schistosoma Japonica

Induction of hepatic fibrosis in mice with schistosomiasis by extracellular microRNA-30 derived from Schistosoma japonicum eggs

Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni

Longitudinal Immune Profiling Highlights CD4+ T Cell Exhaustion Correlated with Liver Fibrosis in Schistosoma japonicum Infection

IL-18 enhances protective effect in mice immunized with a Schistosoma japonicum FABP DNA vaccine

NLRP3 inflammasome inhibition decreases Schistosomiasis japonica-induced granulomatous inflammation and fibrosis in BALB/c mice